SEC Form 4 · accession 0001127602-17-010886

HAEMONETICS CORP · HAE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — EVP and General Counsel

Period of report

Mar 6, 2017

Accepted (ET)

Mar 8, 2017 · 5:21 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000313143

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Mar 6, 2017	A	4,879	$38.43	A	4,879	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Non-qualified Stock Option (Right to Buy)^F2	$38.43	Mar 6, 2017	A	19,490	A	Mar 6, 2018	Mar 6, 2024	Common Stock	19,490	19,490	D
Performance Shares^F3	$0.00	Mar 6, 2017	A	9,758	A	Sep 30, 2019	Dec 31, 2019	Common Stock	9,758	19,516	D

F1Restricted Stock Unit Grant which vest 25% per year over 4 years following the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan.
F2Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.
F3Performance Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Performance Share Unit based on the performance of Haemonetics stock price relative to the Total Shareholder Return of the companies comprising a blended index of the S&P MidCap 400 and S&P SmallCap 600. The number of Performance Share Units (and therefore the number of shares payable) will depend on the Company's stock price performance between October 1, 2016 and September 30, 2019. The Performance Share Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to twice the target amount in column 5. The Performance Share Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d).